在临床前帕金森病和衰老中运动功能障碍的时间和空间动力学
Navya Nair1, Grace Hey2, Alexander Becsey1
1Lillian S. Wells Department of Neurosurgery, College of Medicine, University of Florida, Gainesville, FL 32611, USA.
概括
在M83+/-小鼠模型显示帕金森病 (PD) 步态变化,包括减少四肢摆动和增加步伐频率后,α-synuclein纤维素注射. 这种模型对于临床前PD步态研究很有用.
科学领域:
- 神经科学是一个神经科学.
- 生物医学工程 生物医学工程
- 动物模型 动物模型
背景情况:
- 帕金森病 (PD) 研究经常使用小鼠模型.
- 对于步态分析,M83+/- PD小鼠模型已被研究不足.
- 阿尔法-同核素 (α-syn) 预制纤维素 (PFF) 用于诱导类似PD的病理.
研究的目的:
- 评估M83+/- PD小鼠模型中的步态异常.
- 为了研究α-syn PFF对M83+/-小鼠的步态参数的影响.
- 评估M83+/-模型对临床前PD步态研究的实用性.
主要方法:
- 收集了包括摆动,步伐长度/频率和动力衰竭在内的步行指标.
- 评估使用了DigiGaitTM系统.
- M83+/-小鼠注射了α-syn PFF或作为老年对照使用.
主要成果:
- 接受PFF治疗的小鼠表现出肢体摆动显著减少,步伐频率增加.
- 在年轻的M83+/-+PFF小鼠中,后肢摆动比年长的M83+/-小鼠更大.
- 在接受PFF治疗的小鼠中,前肢,后肢和所有四肢的衰显著增加.
结论:
- M83+/-小鼠表现出与PD一致的显著步态异常.
- M83+/-小鼠模型是PD研究中临床前步态分析的一个有价值的工具.
关键词:
M83+/− - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -帕金森病是帕金森氏症的一种疾病.步态 步态 步态 步态鼠类模型模型更多相关视频
05:39A Fine Motor Task to Study Joint Kinematics in a Preclinical Model of Neurodegenerative Disease
Published on: June 13, 2025
838
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
8.2K
相关概念视频
Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
Parkinson's Disease: Treatment
995
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
995
Neural Regulation
43.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.2K
Pharmacodynamics in Geriatric Patients: Effects of Age
190
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
190
